PIVOT-12: a Phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence

Autor: Eggermont, AMM, Ascierto, PA, Khushalani, NI, Schadendorf, D, Boland, G, Weber, J, Lewis, KD, Johnson, D, Rivalland, G, Khattak, A, Majem, M, Gogas, H, Long, GV, Currie, SL, Chien, D, Tagliaferri, MA, Carlino, MS, Diab, A

Publikováno v: Future Oncology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

Bempegaldesleukin (BEMPEG: NKTR-214) is an immunostimulatory IL-2 cytokine prodrug engineered to deliver a controlled, sustained and preferential IL-2 pathway signal. Nivolumab (NIVO), a PD-L1 inhibitor, has been shown to prolong survival in patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::739d4ac04bcc0a4a655b50961c276ab5
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=7694

EP08.01-014 Tislelizumab versus Docetaxel in Previously Treated Advanced Non-Small Cell Lung Cancer: Final Analysis of RATIONALE-303

Autor: Zhou, C., Huang, D., Fan, Y., Yu, X., Liu, Y., Shu, Y., Ma, Z., Wang, Z., Cheng, Y., Wang, J., Hu, S., Liu, Z., Poddubskaya, E., Disel, U., Akopov, A., Dvorkin, M., Wang, Y., Li, S., Yu, C., Rivalland, G.

Publikováno v: In Journal of Thoracic Oncology September 2022 17(9) Supplement:S342-S343

P-163 Real-world outcomes of cisplatin, capecitabine and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first-line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma

Autor: Waldron, N., Hitchen, N., Deva, S., Rivalland, G., Findlay, M., Lawrence, B.

Publikováno v: In Annals of Oncology July 2021 32 Supplement 3:S155-S155

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

P2.04-13 The Immune Checkpoint, HVEM Contribute to Immune Escape in Non Small Cell Lung Cancer of Lacking PDL1 Expression

Autor: Ren, S., Yu, H., Rivard, C., Suda, K., Caldwell, C., Jr., Rozeboom, L., Ng, T., Rivalland, G., Mitchell, P., Zhou, C., Hirsch, F.

Publikováno v: In Journal of Thoracic Oncology October 2018 13(10) Supplement:S735-S735